RV
RVLPQ.US RVL Pharmaceuticals plc
- Market cap
- USD 1.11K
- P/E
- -
- P/B
- 0.00x
- ROE
- -434.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is RVLPQ.US undervalued?
Graham numberThe Graham number of RVL Pharmaceuticals plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RVL Pharmaceuticals plc fundamental analysis
No fundamental analysis for RVL Pharmaceuticals plc yet.
RVL Pharmaceuticals plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. …
Full company profileRVL Pharmaceuticals plc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
RVL Pharmaceuticals plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 218M | 246M | 264M | 240M | 27.8M | 17.5M | 49.7M | 34.2M |
| Gross Profit | 92.8M | 121M | 124M | 128M | 24.5M | 13.9M | 40.3M | 25.7M |
| Operating Income | -32.0M | -52.1M | -98.5M | 3.94M | -61.7M | -80.5M | -45.7M | -64.6M |
| EBITDA | 21.6M | 62.8M | -664M | -49.8M | -69.7M | -70.3M | -48.2M | -8.91M |
| Net Income | -41.8M | -45.2M | -110M | -271M | -89.0M | -82.8M | -51.7M | -71.0M |
| EPS | -0.98 | -0.98 | -2.42 | -5.17 | -1.47 | -1.23 | -0.58 | -0.71 |
| Balance Sheet | ||||||||
| Total Assets | 979M | 886M | 796M | 463M | 371M | 145M | 129M | 85.4M |
| Total Liabilities | 513M | 466M | 412M | 349M | 277M | 67.9M | 77.4M | 69.1M |
| Shareholders' Equity | 465M | 419M | 384M | 115M | 93.9M | 76.7M | 51.1M | 16.3M |
| Cash & Short-term Investments | 19.6M | 34.7M | 70.8M | 95.9M | 114M | 43.5M | 44.5M | 19.2M |
| Total Debt | 329M | 321M | 269M | 273M | 222M | 47.6M | 57.5M | 58.1M |
| Cash Flow | ||||||||
| Operating Cash Flow | -44.8M | 57.8M | 37.6M | 33.6M | 17.6M | -54.7M | -37.8M | -35.8M |
| Capital Expenditure | 15.9M | 6.90M | 4.14M | 4.04M | 3.13M | 1.78M | 752K | 4.70M |
| Free Cash Flow | -60.7M | 50.9M | 33.4M | 29.5M | 14.5M | -56.5M | -38.6M | -40.5M |
| Ratios | ||||||||
| ROE | -9.0% | -10.8% | -28.6% | -236.2% | -94.8% | -108.0% | -101.2% | -434.9% |
| ROA | -4.3% | -5.1% | -13.8% | -58.5% | -24.0% | -57.3% | -40.2% | -83.1% |
| Net Profit Margin | -19.1% | -18.4% | -41.6% | -112.9% | -320.6% | -473.4% | -104.0% | -207.7% |
| Debt to Equity | 0.71x | 0.76x | 0.70x | 2.38x | 2.36x | 0.62x | 1.13x | 3.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RVL Pharmaceuticals plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 2.00K | 0.00 | - |
| 2017 | - | - | - |
| 2016 | USD 23.3M | 0.54 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns RVL Pharmaceuticals plc
Ownership data of RVL Pharmaceuticals plc is not available yet.
RVL Pharmaceuticals plc company profile
- Company name
- RVL Pharmaceuticals plc
- Ticker
- RVLPQ.US
- ISIN
- IE00BF2HDL56
- Exchange
- USA Stocks
- Listed since
- Oct 18, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 125
- Fiscal year end
- December
- Address
- 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
- Phone
- 908 809 1300
- Website
- rvlpharma.com
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
RVL Pharmaceuticals plc management
2- Mr. Brian A. MarkisonPresident & Principal Financial Officer · born 1959
- Mr. James D. SchaubExecutive VP & COO · born 1983